Drug Combination Details
| General Information of the Combination (ID: C78830) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | PP242 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | ||
| SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | |||
| JeKo-1 | CVCL_1865 | Mantle cell lymphoma | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
PP242 effectively eliminated this deleterious side effect of DNR and synergistically enhanced the anticancer ability of DNR treatment. PP242, especially in combination with DNR, exerts significant antileukemia effects. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia. Anticancer Drugs. 2015 Apr;26(4):410-21. | |||
